Novo Nordisk Chief Floats Direct NYSE Listing as Pipeline Data Clash With Analyst Caution

Novo Nordisk CEO says a direct NYSE listing is possible but not actively pursued, as the drugmaker faces semaglutide patent expiries and pipeline tests.

Novo Nordisk is weighing a deeper foray into American capital markets. In an interview with the Financial Times published Wednesday, CEO Mike Doustdar said the Danish drugmaker is fundamentally open to a direct primary listing on the New York Stock Exchange, a move that would retire its existing American Depositary Receipts. Shares rose 0.8% to EUR 34.73 in pre-market trading on the news.

The rationale is straightforward: the company's shareholder base has been shifting away from Scandinavia for two decades, and the United States now accounts for more than half of group revenue, including the bulk of sales for diabetes and obesity drugs Wegovy and Ozempic. Swapping ADRs for directly traded ordinary shares could ease access for US institutions, mirroring a step rival AstraZeneca took earlier this year.

Doustdar was quick to temper expectations, however. While he sees clear merits in a US listing, he said the company is not actively pursuing the option in day-to-day operations. The topic has been debated internally for years, but no active dialogue with exchange representatives has taken place since he took the helm last year. Copenhagen remains Novo Nordisk's primary trading venue for now.

A Capital Markets Day That Left Questions Open

The listing chatter lands in the middle of a rough stretch for the stock. During Wednesday's session the shares fell 2.0% to EUR 33.77, extending a softer tone that set in Monday with a capital markets day in London. The guidance presented there failed to fully satisfy investors looking for clear strategic direction.

Sell-side analysts added to the cautious mood. Deutsche Bank trimmed its price target to DKK 245 from DKK 265, while Jefferies rated the stock "Hold." The question now facing shareholders is whether the recent decline already discounts fundamental risks, or whether the handover to future growth drivers will prove more protracted than hoped.

Semaglutide's Patent Cliff Is the Central Test

Everything hinges on how revenue is composed. Semaglutide, the diabetes and obesity franchise at the heart of the current business, drives roughly 75% of sales in 2026, according to media reports. Doustdar acknowledged Monday that the compound will lose key patent protection early in the next decade.

The US expiry in 2032 carries particular weight — the American market generated more than half of Novo Nordisk's global revenue last year. Success therefore depends on bringing successor products to market in time to absorb the looming revenue gap. Pull off that transition without painful margin or volume erosion and the growth story holds; let it slip, or see demand fall short of lofty benchmarks, and a re-rating of the entire business model becomes the risk.

Clinical Data Offer a Counterweight

On the optimistic side, the company argues it has enough in the clinic to offset the patent expiries. Doustdar said Monday that Novo Nordisk aims to launch at least five so-called multi-blockbusters by 2030, targeting revenue growth on par with other large pharmaceutical companies.

Recent trial results lend support. In the Phase 3 REIMAGINE 5 study of adults with type 2 diabetes, the CagriSema combination at a 1.0 mg/1.0 mg dose delivered 12.4% weight loss after 60 weeks, beating tirzepatide at 5 mg, which achieved 9.1%, while also showing non-inferior HbA1c reduction. In the REDEFINE 9 trial, the same dose produced 21% weight loss after 68 weeks in overweight or obese adults versus placebo.

Alongside the pipeline, Novo Nordisk is putting cash to work through buybacks: between February 4 and September 18, it repurchased 34,174,179 of its own B shares for a transaction volume of roughly DKK 9.63 billion.

Competition and Expiries Keep Margin Pressure Alive

Not every comparison has gone Novo Nordisk's way. Media reports indicate CagriSema reached 23% weight loss in one Phase 3 trial, while Eli Lilly's tirzepatide hit 25.5%, with non-inferiority not demonstrated in that study. Should rivals expand their share of the lucrative obesity market, margins could come under pressure sooner than market participants have modeled. Heavy reliance on semaglutide, combined with the 2032 US patent expiry, leaves little room for late-stage setbacks.

Morgan Stanley responded nearly two weeks ago with a downgrade to "Underweight," underscoring rising skepticism in institutional circles. Competitive pressure is also visible in the numbers: LSEG data suggest Lilly's Zepbound will outsell Wegovy by more than USD 7 billion this year. To secure future growth, Novo Nordisk is focusing beyond acquisitions on oral tablet therapies, which are expected to capture a growing share of the global obesity treatment market in the years ahead.

What Investors Should Watch Now

Direction over the coming months rests on confirmation of the clinical pipeline. At EUR 33.77, the stock sits 38% below its 52-week high of EUR 54.86 — a 37% discount on the secondary article's measure. As long as support holds near the 52-week low of EUR 30.25, a bottoming scenario at reduced levels stays intact, leaving room for a re-rating of pipeline potential on the prospect of new approvals. Should that level give way under sustained selling, market participants are likely to price in the long-term patent cliffs more aggressively. The next concrete catalyst is regulatory progress on the announced blockbuster candidates, whose approval efficiency will be the yardstick for the 2030 timeline.